One-Year Graft Patency for Elective CABG Affected by Baseline Glycemic Control
Researchers assessed the relationship between 1-year vein graft patency, baseline hemoglobin A1c, and antiplatelet therapy in patients who have received CABG.
Researchers assessed the relationship between 1-year vein graft patency, baseline hemoglobin A1c, and antiplatelet therapy in patients who have received CABG.
Differences in mortality and MACE were evaluated in patients with ACS managed with PCI who were receiving ticagrelor or clopidogrel.
A meta-analysis was conducted to compare short DAPT with de-escalation in patients with acute coronary syndrome who have received percutaneous coronary intervention.
Ticagrelor without aspirin offered no additional benefits compared with conventional dual antiplatelet therapy in patients undergoing PCI for either CAD or ACS.
Genotype-guided therapy improved outcomes in patients who were CYP2C19 intermediate and poor metabolizers.
Switching DAPT after acute coronary syndrome provides benefits regardless of initial platelet reactivity.
The European Society of Cardiology and European Association for Cardio-Thoracic Surgery have released a focused update on dual antiplatelet therapy use in coronary heart disease.
No significant differences were observed between dual antiplatelet therapy and aspirin alone following coronary artery bypass grafting in patients with diabetes.
All-cause death plus hospitalization possibly from bleeding were reduced in both rivaroxaban groups compared with the reference group.
Long-term dual antiplatelet therapy was associated with reduced MACE in patients who underwent complex percutaneous coronary intervention.